Patrick McManamny is a partner in our Melbourne biotechnology team.
He regularly counsels clients in relation to filing and management of international patent portfolios, freedom-to-operate issues, patentability and due diligence. Patrick has substantial experience in conducting due diligence in relation to biological therapeutics such as antibodies, proteins, peptides, gene therapy and cell therapies and processes for their manufacture. He also has experience in diagnostics and drug screening methods. Patrick was endorsed in the IAM Prosecution recommended list in 2022 and 2023.